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Abstract There are several hypotheses on functional
neuronal networks that modulate mood states and which
might form the neuroanatomical basis of bipolar disorder.
The thalamus has been reported to be a key structure within
thecircuitsthatmodulatemoodstatesandmightthusplayan
important role within the aetiology of the bipolar affective
disorder. Nevertheless, structural brain imaging studies on
the thalamus volume of bipolar patients have shown heter-
ogeneous results. Using structural MRI scanning, we com-
pared the thalamus volume of 41 euthymic bipolar patients
tothethalamusvolumeof41well-matchedhealthycontrols.
Taking the concomitant medication as a co-variable within
the patient group, the analysis of variance revealed a sig-
niﬁcantly smaller relative volume of the right thalamus in
patients not treated with lithium when compared with
healthy controls. In contrast, there are no signiﬁcant differ-
encesconcerningthethalamusvolumebetweenalleuthymic
bipolar patients and healthy controls. The study only shows
ﬁndings of a transverse section. No longitudinal analysis
was performed. More detailed information on patients’
pharmacological histories could not be obtained. In con-
clusion, this result may be interpreted as an indication of the
impact of the thalamus in the pathogenesis of the bipolar I
disorder and emphasises the need for further longitudinal
studies in bipolar patients with special attention paid to the
concomitant medication, in particular to the role of lithium.
Keywords Bipolar affective disorder  MRI 
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Introduction
There are several hypotheses on functional neuronal net-
works that modulate mood states and which might form the
neuroanatomical basis of bipolar disorder. Two suggested
loops of mood-regulation are (1) the so-called limbic–
thalamic–cortical circle consisting of the amygdala, the
mediodorsal nucleus of the thalamus and the medial and
ventrolateral prefrontal cortex, and (2) the so-called lim-
bic–striatal–pallidal–thalamic circle which includes the
striatum, the ventral pallidum and the above-mentioned
anatomical structures of the limbic–thalamic–cortical circle
[23]. The thalamus has been reported to be a key structure
within these circuits that modulates human emotional,
cognitive and social behaviour [24]. It serves as a relay
station to the cerebral cortex and to limbic structures [9], as
a ‘‘critical node’’ in forebrain circuitry [23], and it pro-
cesses sensory information and integrates activity within
areas of the forebrain.
In patients with bipolar disorder, the functioning of their
emotional, cognitive and social behaviour can be disturbed
[24]. The thalamus might, therefore, be a key structure
linked to the aetiology of bipolar disorder [23]. This pre-
sumption is supported by several case reports [2, 8, 25],
e.g. a patient presenting a transient manic mood state after
an ischaemic lesion in both dorsolateral thalami [2]o ra
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lamic infarction [8].
Despite extensive research efforts in the last years, the
neuropathogenesis of bipolar disorder remains poorly
understood. So far, it might be described as a dysfunction in
anterior sub-cortico-prefrontal limbic networks, speciﬁcally
within the prefrontal–striatal–thalamic circuits and inter-
connected areas such as the amygdala and the midline cer-
ebellum. Structural changes in these loops and the
interconnectedareasmayleadtotheirdysfunctionandtothe
development of affective disorders [19] on the basis of a
so-called structural vulnerability. Several authors attempted
a characterisation of structural changes in patients with
bipolar disorder and mood disorders in general in review
articles and meta-analyses. Overall, the results of structural
brain abnormalities in bipolar patients, adults and children/
adolescentswere inconsistentandvariedconsiderably.With
regard to thalamus volume, reviews and meta-analyses
showedinhomogeneity[12,19,24].Inthemostrecentmeta-
analysis,Kemptonetal.[10]reportednosigniﬁcantchanges.
Taken together, changes in thalamus volume in bipolar
patients seem to underlie more differentiated modulations
than solely the diagnosis of a bipolar affective disorder.
More concise studies with clinical subsamples deﬁned by
symptom proﬁle, chronicity, severity and medication status
areneededtoclarifythecurrentheterogeneousﬁndings[19].
The aim of this study was to examine the thalamus
volume of a large sample of well-matched euthymic
patients with bipolar I disorder in comparison to healthy
controls by structural brain imaging with special interest to
the co-variable of lithium treatment. Other co-variables
were the age of onset of the disease, number of previous
manic or depressive episodes, medication with mood sta-
bilizers other than lithium, antipsychotic medication and
prior psychotic symptoms. On the basis of this matched
sample, we were able to minimise the potential inﬂuence of
gender, handedness, age, education and manic or depressed
episodes on the thalamus volume, and to try to answer the
question of whether structural changes emerge only in
distinct subgroups of bipolar patients.
Methods
Subjects
Forty-one euthymic patients with bipolar I disorder and 41
healthy controls matched with respect to age, gender,
handedness and education participated in the study (see
Table 1). In this sample, the age of onset of the disease was
28.6 (±9.6) years, duration of illness was 13.9
(±10.6) years and patients exhibited on average 7.9 (±8.3)
manic and 7.9 (±7.6) previous depressive episodes. The
scores of the MADRS [15] (4.6 ± 3.5) and YMRS [28]
(2.5 ± 2.8) scales indicated the patients’ euthymic mood
state. 15 patients received lithium; 26 never received lith-
ium, but amongst these 11 received other mood stabilizers,
4 ﬁrst- and 14 second-generation antipsychotics. In total,
14 patients received antidepressants, of whom 5 were
taking lithium. All patients were on stable medication at
the time of imaging. The patients receiving lithium had
been on a stable dose for at least 6 months. Lithium serum
levels were obtained in the same week as the MRI scan.
Between patients with and without lithium treatment, there
was no signiﬁcant difference in age at the time of the MRI
scan (F = 1.4, df = 1,37, P = 0.24), education (F = 1.6,
df = 1,37, P = 0.21), age of onset of the disease (F = 0.2,
df = 1,35, P = 0.64), duration of illness (F = 1.4,
df = 1,37, P = 0.24), number of manic episodes (F = 0.1,
df = 1,34, P = 0.78), number of depressive episodes (F =
0.1, df = 1,34, P = 0.82), MADRS (F = 1.9, df = 1,34,
P = 0.18), YMRS (F = 0.7, df = 1,33, P = 0.41) or
family history for psychiatric diseases (v
2 = 4.5, df = 2,
P = 0.11).
Written informed consent was obtained from all subjects
prior to their inclusion in the study and the study was
approved by the local ethics committee and, therefore,
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki. Patients with
bipolar disorder were consecutively recruited from the
outpatient unit of the Department of Psychiatry and Psy-
chotherapy of the Saarland University Hospital between
December 2003 and October 2006. The diagnosis of
bipolar I disorder was conﬁrmed using the German version
of the Structural Clinical Interview for DSM-IV [26].
Patients with any other axis I disorder in particular alcohol
dependence and medical and neurological illnesses that
might have an inﬂuence on brain structure were excluded.
The healthy controls exhibited no past or present psychi-
atric, neurological or medical disorder and had no positive
family history of psychiatric disorders. They were recruited
from the general population via advertising in newspapers.
Imaging
Magnetic resonance imaging scanning was performed on a
1.5-T Magnetom (Siemens, Erlangen). A T1-weighted,
MPRAGE sequence (TE = 4.42 ms, TR = 1,900 ms,
TI = 700 ms, ﬂip angle = 15, FOV 256 9 256 mm) of
176 consecutive slices was acquired with a voxel size of
1m m
3. The images were re-orientated and aligned parallel
to the anterior–posterior commissural axis and the origin
was set to the anterior commissure. To measure the thal-
amus volume, the software MRIcro by Chris Roden was
used. A rater blind to diagnosis and genotype (VF) deter-
mined the thalamus volume by direct manual tracing of the
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123boundaries. As limits we used the interne capsule laterally,
the third ventricle medially, ventrally the hypothalamus
and dorsally the second ventricle. In the following step, the
ﬁrst visible part of the thalamus was detected in the coro-
nary level. As orientation points, we used the above-
described marks and the Luschka foramen. The thalamus
was marked in each slice in a frontooccipital direction. The
two adjacent levels were used as controls. Total grey
matter volume refers to the grey matter volume of the
entire brain. After the segmentation of grey and white
matter and cerebrospinal ﬂuid by means of the freely
available Statistical Parametrical Mapping Program
(SPM99) of the Wellcome Trust Centre for Neuroimaging,
the total grey matter was calculated automatically using our
own algorithm. Relative volume was computed by dividing
thalamus volume to the total grey matter volume.
Statistical analysis
For statistical analyses, SPSS 15 for Windows was used.
Signiﬁcance level was a = 0.05. All tests were two tailed.
Dependent variables were right and left relative thalamus
volumes and total grey matter volume, independent vari-
able was diagnostic group (bipolar patients, healthy
controls).
Identifying intervening covariates and factors
Two-way analysis of variance (ANOVA) adjusted for
diagnostic group was used to determine if there were
signiﬁcant inﬂuences on the dependent variables of
gender or hand preference. Bivariate product moment
correlations were calculated separately for control sub-
jects and bipolar patients intending to analyse if age and
duration of education had an inﬂuence on the dependent
variables.
Effect of diagnosis
Analysis of covariance (ANCOVA) was computed to
analyse if there were signiﬁcant diagnosis differences for
total grey matter volume. This analysis was performed with
Table 1 Comparison of demographical and clinical data regarding healthy controls (HC), the total sample of bipolar patients (BP) and its two
subsamples with lithium-treated (Li) and non lithium-treated (non-Li) patients
Controls Bipolar patients
HC BP total Subsample
non-Li
Subsample
Li
HC versus
BP (P)
Non-Li
versus Li (P)
Number of participants 41 41 24 15
Gender (female/male) 20/21 21/20 12/12 8/7 0.83
b 0.84
b
Handedness (right/not right) 32/9 36/5 21/3 14/1 0.24
b 0.56
b
Age (in years) (mean ± SD) 42.2 ± 10.8 43.2 ± 12.2 41.1 ± 12.8 45.9 ± 11.3 0.70
a 0.24
a
Education proband (in years) (mean ± SD) 14.2 ± 2.7 14.1 ± 2.9 14.5 ± 2.8 13.3 ± 3.0 0.84
a 0.21
a
Education father (in years) (mean ± SD) 12.9 ± 2.3 13.0 ± 2.6 13.2 ± 2.7 12.9 ± 2.5 0.89
a 0.72
a
Education mother (in years) (mean ± SD) 11.0 ± 2.1 11.1 ± 2.2 11.4 ± 2.2 10.6 ± 2.2 0.87
a 0.32
a
Age of onset (in years) (mean ± SD) 28.6 ± 9.6 28.0 ± 9.9 29.5 ± 9.3 0.64
a
Duration of illness (in years) (mean ± SD) 13.9 ± 10.6 12.3 ± 10.5 16.5 ± 10.5 0.24
a
Previous manic episodes (mean ± SD) 7.9 ± 8.3 8.2 ± 8.5 7.4 ± 8.3 0.78
a
Previous depressive episodes (mean ± SD) 7.9 ± 7.6 7.7 ± 7.4 8.3 ± 8.1 0.82
a
MADRS (mean ± SD) 4.6 ± 3.5 5.2 ± 3.1 3.5 ± 3.9 0.18
a
YMRS (mean ± SD) 2.5 ± 2.8 2.8 ± 3.0 2.0 ± 2.3 0.41
a
Lithium yes/no 15/24
Lithium level (mmol/l) (mean ± SD) 0.0 ± 0.0 0.7 ± 0.2 \0.0005
a
Other mood stabilizers yes/no 11/28 2/22 9/6 \0.0005
b
Antipsychotics no/ﬁrst/second generation 20/4/14 13/2/9 7/2/5 0.85
b
Antidepressants yes/no 14/25 9/15 5/10 0.79
b
Family history depression, bipolar/other
psychiatric diagnosis/none
9/7/24 5/2/16 4/5/6 0.11
b
Prior psychotic symptoms (yes/no) 29/10 16/8 13/2 0.16
b
MADRS Montgomery Asberg Depression Scale, YMRS Young Mania Rating Scale, m mean, SD standard deviation
a P values (two tailed) based on ANOVA
b P values (two tailed) based on exact v
2 tests
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123the independent factors diagnosis and gender and the
covariates age and duration of education. As gender, age,
education and hand preference showed no signiﬁcant
impact on thalamus volumes, univariate ANOVA with
factor diagnosis and no other intervening variables were
performed to determine whether there were differences
between bipolar patients and controls for right and left
relative thalamus volume.
Effect of lithium, other medication and clinical variables
The three groups, bipolar patients with lithium treatment,
without lithium treatment and healthy controls, were
compared on thalamic volume differences with ANOVA
and subsequent two-group comparisons using Bonferroni’
adjusted P values.
An ANOVA design was applied to analyse if there was a
signiﬁcant impact of mood stabilizers other than lithium,
psychotic symptoms or antipsychotic drugs. Pearson cor-
relations were computed to analyse if disease duration, age
at onset of the disease and the number of previous
depressive or manic episodes had an inﬂuence on thalamic
volumes.
Results
Identifying intervening covariates and factors
With respect to gender, statistical tests showed signiﬁcantly
(F = 7.1, df = 1,8, P = 0.009) more total grey matter in
male subjects, but no signiﬁcant differences regarding the
left and right relative thalamus volume. No signiﬁcant
effect of hand preference on total grey matter volume or
thalamus volume was detected, but a correlation was found
between education and total grey matter volume (controls
r = 0.6, P\0.0005, bipolar patients r = 0.4, P = 0.008).
Total grey matter volume showed a signiﬁcant negative
correlation with age (controls r =- 0.5, P = 0.001,
bipolar patients r =- 0.5 P = 0.003), but there was no
signiﬁcant correlation of age with the relative thalamus
volume.
Effect of diagnosis
Grey matter volume was not signiﬁcantly different between
the two diagnostic groups. In addition, there was no sig-
niﬁcant difference in thalamus volume between patients
with bipolar I disorder and healthy controls. However,
there was a trend for a volume decrease in bipolar patients
for the left relative thalamus volume (F = 3.5, df = 1,8,
P = 0.066).
Effect of lithium, other medication and clinical
variables
There were no signiﬁcant differences in demographic
variables between patients treated with lithium (N = 15)
and those not receiving a lithium medication (N = 24) (see
Table 1). In a three-group analysis, the factor lithium
showed a signiﬁcant inﬂuence on the relative right thala-
mus volume in patients with bipolar I disorder (F = 3.4,
df = 2,8, P = 0.040). A subgroup analysis with Bonferroni
adjustment for three comparisons showed a signiﬁcant
decrease in right thalamus volume in patients not treated
with lithium as compared to healthy controls (P = 0.036).
The lithium-treated patients showed no difference in thal-
amus volume as compared to the sample of healthy con-
trols or the patients not treated with lithium (see Tables 2,
3, see Fig. 1). No impact of lithium on the grey matter
volume could be detected.
Mood stabilizers other than lithium showed no signiﬁ-
cant inﬂuence on relative thalamic volumes. Amongst
bipolar patients, there was no signiﬁcant thalamus volume
difference between patients with and without psychotic
symptoms. Total grey matter volume was signiﬁcantly
decreased in patients treated with antipsychotic drugs
(P = 0.023), but there was no signiﬁcant inﬂuence of
Table 2 Thalamus volume divided by psychiatric diagnosis (P values based on ANOVA results)
HC BP Diff. % BP versus HC df F P
All individuals (N)4 1 4 1
Grey matter volume (cm
3 mean ± SD) (GM) 713.8 ± 71.6 725.1 ± 77.8 1.6 1,8 1.2 0.50
Absolute thalamus volume
Right (cm
3 mean ± SD) 6.88 ± 0.87 6.68 ± 0.80 -3.0 1,8 1.2 0.27
Left (cm
3 mean ± SD) 6.71 ± 0.82 6.59 ± 0.86 -1.8 1,8 0.4 0.51
Relative thalamus volume (thalamus/GM)
Right (% of GM mean ± SD) 0.97 ± 0.11 0.92 ± 0.10 -4.3 1,8 3.5 0.066
Left (% of GM mean ± SD) 0.94 ± 0.10 0.91 ± 0.10 -3.3 1,8 2.1 0.15
HC healthy controls, BP bipolar patients, N number, m mean, SD standard deviation, Diff. % difference in percent terms
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123antipsychotic drugs on left or right thalamus volume. There
were no signiﬁcant correlations between relative thalamus
volumes and the duration of the disease, the age of onset
and the number of previous depressive or manic episodes.
Discussion
In this study, we investigated the thalamus volume in
patients with bipolar I disorder treated with or without
lithium as compared to a well-matched group of healthy
control subjects. We found a signiﬁcantly decreased rela-
tive right thalamus volume in lithium-free bipolar patients
in contrast to healthy controls, whereas the lithium-treated
bipolar patients showed no difference to the thalamus
volume of the healthy control group. No signiﬁcant dif-
ferences concerning the thalamus volume were detected
between the whole patient group and control subjects.
These results are consistent with those of Foland et al.
who recently reported an increase in the volume of hip-
pocampus and amygdala in patients treated with lithium in
comparison to those without such treatment [7]. With
respect to the thalamus, Monkul et al. [13] showed an
enlargement trend for the left thalamus in lithium-treated
youths and adolescents in comparison to a lithium-free
group of patients. Comparing patients with treatment
including lithium or valproic acid with patients not
receiving these substances, Chang et al. [4] also observed a
Table 3 Thalamus volume divided by psychiatric diagnosis/bipolar patients with lithium-(Li) versus without lithium treatment (non-Li)
HC BP, subsample Factor
diagnosis/LiBP
Non-LiBP
versus HC
Diff. %
Non-Li
versus
HC, P
BP Li
versus
HC Diff. %
BP Li
versus
HC, P
Non-Li Li df F P
All individuals (N)4 1 2 4 1 5
Grey matter volume
(cm
3 mean ± SD) (GM)
a
713.8 ± 71.6 729.0 ± 74.6 722.8 ± 87.1 2,70 0.8 0.46 2.1 1.0 1.3 0.58
Absolute thalamus volume
a
Right (cm
3 mean ± SD) 6.88 ± 0.87 6.54 ± 0.86 6.83 ± 0.70 2,70 3.6 0.031 -4.9 0.082 -0.8 1.00
Left (cm
3 mean ± SD) 6.71 ± 0.82 6.47 ± 0.86 6.74 ± 0.91 2,70 2.7 0.072 -3.6 0.1 0.5 0.97
Relative thalamus volume [thalamus/GM (%)]
b
Right (% of GM mean ± SD) 0.97 ± 0.11 0.90 ± 0.10 0.95 ± 0.08 2,77 3.4 0.040 -6.9 0.036 -1.7 1.00
Left (% of GM mean ± SD) 0.94 ± 0.10 0.89 ± 0.11 0.94 ± 0.08 2,77 2.3 0.11 -5.5 0.11 -0.8 1.00
HC healthy controls, BP bipolar patients, N number, m mean, SD standard deviation, Diff. % difference in per cent terms
P values for the subgroup analyses were Bonferroni adjusted for three comparisons
a Analysis method: ANCOVA (factors diagnosis/lithium, covariates age, duration of education)
b Analysis method: ANOVA (factor diagnosis/lithium)
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Fig. 1 Relative thalamus volume in bipolar patients with and without lithium treatment and controls. Figure 1 shows the mean and the 95%
conﬁdence intervals as error bars of control subjects and bipolar patients without and with lithium treatment
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123trend for a larger left thalamus in the lithium or valproic
acid-treated patients. In contrast, one study did not show
any difference between lithium-treated patients and those
not treated with lithium, but included only a relatively
small number of patients [3].
Taken together, there are not many studies which use
psychiatric medication, in particular mood stabilizers, as a
variable within the analysis of structural ﬁndings in bipolar
patients, although several studies investigated the effect of
psychotropic medication and antipsychotics in particular in
patients with schizophrenia [20]. The effect of psychotro-
pic medication on grey matter though has been described as
a possible cause for discrepancies in structural ﬁndings in
bipolar patients. In our study, we detected a signiﬁcantly
decreased total grey matter volume in patients treated with
antipsychotics. We assume that the effects of antipsy-
chotics in bipolar patients would be similar to those in
patients suffering from schizophrenia [20]. Nevertheless, as
only four of our patients received ﬁrst-generation antipsy-
chotics, it has to be considered that the reduction in the
total grey matter of the overall bipolar sample is due to
factors yet unknown. Concerning mood stabilizers espe-
cially the role of lithium in a patients’ medication seems to
be crucial: Patients treated with lithium showed a signiﬁ-
cantly increased volume of grey matter [16, 18], an effect
we were not able to detect in our study. A recently per-
formed meta-regression showed that grey matter volume
increased amongst patients with bipolar disorder when
compared with controls when the proportion of patients
using lithium increased [10]. A neurotrophic effect of
lithium has been postulated [1], and the question raised as
to whether lithium exerts great effects in discrete brain
regions that have previously been associated with brain
atrophy [16]. Moore et al. [17] even revealed signiﬁcant
differences in regional analyses between responders and
non-responders to a lithium treatment: amongst bipolar
patients only responders showed a signiﬁcant increase in
the grey matter volume in the prefrontal cortex and at trend
level an increase in volume in the left subgenual prefrontal
cortex.
A study by Scherk et al. [21] using voxel-based mor-
phometry did not reveal any signiﬁcant correlations of grey
or white matter volume with lithium, mood stabilizers or
antipsychotics. Using the same method Monkul et al. [14]
showed no effect on total brain and total grey matter vol-
ume but a signiﬁcant increase in the total white matter and
the grey matter volume of the left and right dorsolateral
prefrontal cortex and the left anterior cingulate after a
4 weeks lithium administration in healthy individuals.
Another VBM study showed that lithium-treated patients
have a regional grey matter loss in the left middle-occipital
gyrus as compared to healthy controls and decreased grey
matter in right orbital gyrus as compared to patients not
taking lithium [6]. The authors suggested that regional
effects exerted by lithium might be unrelated to its neu-
rotrophic effects.
So far, there is not much knowledge about the mode of
functioning of lithium at a molecular level. It was postu-
lated to increase the neuropil, the volume of grey matter
and to induce higher NAA concentrations [1, 16, 18].
However, the exact mechanism remains unknown. Studies
suggest that it works at the molecular level to boost factors
such as, bcl-2 [5], a cytoprotective protein which has
neurotrophic effects and improves axon regeneration [16],
brain-derived neurotrophic factor and provides a protection
against stress-induced reductions in neuronal integrity [11,
27]. A protection of neural progenitor cells from apoptosis
is also described [22]. How these changes exactly work to
impact brain morphology and stabilize mood is unknown.
According to former studies and to our results, lithium
might exert a speciﬁc effect on a central region of human
emotional processing and should, therefore, be particularly
considered in the investigation of bipolar disorder.
The generally heterogeneous results in structural imag-
ing of the thalamus volume described in the introduction
could be due to several methodical limitations, e.g. the
inclusion of patients with differing severity of symptoms,
different affective states, ﬁrst-episode and chronically ill
patients into the same studies. Sometimes co-morbid
alcohol or substance misuse was ignored or the patients’
medication not considered. As mentioned in the introduc-
tion changes in volume of brain structure may underlie
more differentiated modulation procedures than solely the
diagnosis of a bipolar affective disorder [29]. In this point,
especially the role of medication seems essential. To
reduce the possible inﬂuence of concomitant factors, we
included only euthymic patients with bipolar I disorder
with no history of alcohol abuse or dependence and
investigated a sufﬁciently large sample. All patients were
treated with stable medication over several months.
Another strength of our study is the presence of a healthy
group of well-matched control subjects which is missing in
the above-mentioned study of Foland et al. [7]. A limitation
of our study is that the ﬁndings are the results of a trans-
verse section and not of a longitudinal analysis. In addition,
it was not possible to provide more detailed information
about the exact duration of the lithium and antipsychotic
treatment of the respective patients and for what reason the
sample of the lithium-free patients had never received this
medication. Future studies including larger numbers of
patients might show a difference in thalamus volumes
between the groups of patients treated or not treated with
lithium which we were not able to demonstrate in our
study.
Taken together, the present ﬁndings are consistent with
the view that treatment with lithium may normalise right
606 Eur Arch Psychiatry Clin Neurosci (2010) 260:601–607
123thalamus volume which is decreased without lithium
treatment in bipolar I disorder. Further longitudinal studies
are needed to clarify the role of thalamus volume in bipolar
disorder and the inﬂuence effect of lithium on it.
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